CLINICAL_TRIALS
trial_result
· 2018-10-15
Clinical Trial Update: Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma [Phase 2]
Summary
Phase 2 trial evaluating Glembatumumab Vedotin in recurrent or refractory osteosarcoma has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Osteosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2018-10-15